Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability

Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability

Summary: CD276/B7-H3 represents a promising target for cancer therapy based on widespread overexpression in both cancer cells and tumor-associated stroma. In previous preclinical studies, CD276 antibody-drug conjugates (ADCs) exploiting a talirine-type pyrrolobenzodiazepine (PBD) payload showed pote...

Full description

Bibliographic Details
Main Authors: Yang Feng, Jaewon Lee, Liping Yang, Mary Beth Hilton, Karen Morris, Steven Seaman, Veera V. Shivaji R. Edupuganti, Kuo-Sheng Hsu, Christopher Dower, Guojun Yu, Daeho So, Pradip Bajgain, Zhongyu Zhu, Dimiter S. Dimitrov, Nimit L. Patel, Christina M. Robinson, Simone Difilippantonio, Marzena Dyba, Amanda Corbel, Falguni Basuli, Rolf E. Swenson, Joseph D. Kalen, Sreedhar Reddy Suthe, Myer Hussain, James S. Italia, Colby A. Souders, Ling Gao, Martin J. Schnermann, Brad St. Croix
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Cell Reports
Subjects:
CP: Cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124723015152

Internet

http://www.sciencedirect.com/science/article/pii/S2211124723015152

Similar Items